Cell Line Ranking using Microscale Bioreactor Technology - Stirred not Shaken
- Read Whitepaper
If cell lines expressing therapeutic mAbs are ranked accurately and optimized for product expression using microscale bioreactor models early in development, then manufacturing costs can be reduced significantly. Because the price per patient for monoclonal antibody (mAb) therapies runs into thousands of Euros each year . These therapies cost considerably more to manufacture than small molecules .
During the cell screening, the chances of isolating a high producing clone for products such as mAbs is improved by maximising the number of cell lines that are evaluated. Traditionally, shake flasks and benchtop bioreactors have been used to select the most productive cell lines, as well as to define optimal media, feed and bioprocessing conditions.